The Department of Justice has filed a motion to participate in opioid litigation settlement talks as a "friend of the court." 

Sandoz may have to wait a little longer for a clear shot at launching a biosimilar to Amgen's anti-inflammatory blockbuster Enbrel.

Prove it, GSK. So says a judge in the Coreg "carve-out" patent case that last year ended in a $235 million judgment against generics maker Teva.

AbbVie scored a major reduction of damages in a retrial of an AndroGel liability case brought by plaintiff Jesse Mitchell.

Endo, Teva and a Japanese drugmaker have agreed to fork over more than $270 million to resolve a class-action suit over Lidoderm.

Federal prosecutors say they'll show Novartis traded fancy dinners—and in some cases, jobs for physicians' relatives—to boost prescription numbers.

Under a 2003 agreement, Array BioPharma says AstraZeneca needs to pony up $192 million.

The feds charged five doctors over accepting Insys' bribes and said they've secured cooperation from two former employees.